

# Lexaria Bioscience Corp.

08:19 13 Feb 2020

## Lexaria Bioscience explains benefit of its CBD infused powders against backdrop of consumer concerns on potency

Lexaria Bioscience Corp (CSE:LXX)(OTCMKTS:LXRP) has highlighted that its patented DehydraTECH technology-enabled CBD infused powders are now available for sale across the US, against the backdrop of consumer concern over cannabinoid potency.

DehydraTECH turns cannabis and hemp oils into stabilized powders, which allows for faster absorption into the human bloodstream.

The process also preserves the cannabinoids contained within and mitigates microbiological growth for longer shelf life, noted Lexaria on Thursday.

**READ:** Lexaria Bioscience beefs up licensing deal providing DehydraTECH to Cannadips Cannabis

The firm sells its pre-processed CBD/hemp DehydraTECH powders directly to manufacturers for use within their own products.

In a statement, Lexaria cited a European study, which discovered that THC potency tends to degrade by over 20% per year, and CBD potency by over 10% per year.

It also noted that last year, two of North America's largest cannabis companies announced multi-million-dollar losses on aged cannabis inventories.

During the Fall last year, American farmers delivered the largest CBD/hemp crops in US history, leading to another glut of supply and plummeting prices for oils containing CBD, the firm added.


In addition, certain types of packaging, such as polystyrene, can also absorb between 60% and 100% of the THC within, if the consumer products have not been stabilized such as is possible with the DehydraTECH technology.

Contact the author at [giles@proactiveinvestors.com](mailto:giles@proactiveinvestors.com)

**Price:** 0.37

**Market Cap:** \$33.15 m

### 1 Year Share Price Graph



### Share Information

**Code:** LXX

**Listing:** CSE

52 week	High	Low
	1.27	0.31

**Sector:** Cannabis

**Website:** [www.lexariabioscience.com](http://www.lexariabioscience.com)

### Company Synopsis:

*Lexaria Bioscience Corp has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules. Many vitamins, drugs, supplements and other beneficial molecules are lipophilic (i. e.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).